What is ThinkCyte?
Founded in 2016, ThinkCyte is at the forefront of developing transformational single-cell technologies. By integrating advanced hardware, machine learning, and biotechnology, the company aims to accelerate biological discoveries and enable the development of novel treatments and diagnostics. ThinkCyte's mission is to empower scientists and biomedical professionals with cutting-edge tools, positioning itself as a key player in the rapidly evolving life sciences sector. The company's focus on multidisciplinary technologies highlights its commitment to innovation and comprehensive solutions.
How much funding has ThinkCyte raised?
ThinkCyte has raised a total of $97.3M across 4 funding rounds:
Series A
$15.3M
Series B
$26M
Private Equity
$24M
Series C
$32M
Series A (2020): $15.3M with participation from SPARX Group, SBI Group, Fuyo General Lease, and Itochu Technology Ventures, Inc
Series B (2021): $26M led by SBI Group, Mirai Creation Fund/SPARX Asset Management, ITOCHU Technology Ventures, Sumitomo Mitsui Trust Investment Co., and Sysmex
Private Equity (2023): $24M supported by Sumitomo Mitsui Trust Bank, Nomura Holdings, and Tokyo Century Corporation
Series C (2024): $32M featuring SMBC Venture Capital
Key Investors in ThinkCyte
SBI Group
SBI Group is a diversified financial services conglomerate with a broad investment portfolio, likely focusing on technology and growth-stage companies within the life sciences sector.
Mirai Creation Fund/SPARX Asset Management
Mirai Creation Fund, managed by SPARX Asset Management, typically invests in innovative technologies and companies with high growth potential, aligning with ThinkCyte's biotech focus.
ITOCHU Technology Ventures
ITOCHU Technology Ventures, the venture capital arm of ITOCHU Corporation, invests in leading information technology companies, suggesting a strategic interest in the technological underpinnings of ThinkCyte's platform.
What's next for ThinkCyte?
With the recent influx of major enterprise-level funding and a strategic investment, ThinkCyte is poised for significant expansion and further technological advancement. This capital infusion is expected to fuel research and development, enhance its product offerings, and potentially broaden its market reach. The company's strategic positioning suggests a focus on scaling its operations and solidifying its market leadership in the biotechnology and life sciences research domain. Future developments will likely involve the application of its single-cell technology to a wider range of therapeutic areas and diagnostic applications.
See full ThinkCyte company page
